Vogel Marc, Gade Jonas, Timm Bernd, Schürmann Michaela, Auerbach Hendrik, Nüsken Frank, Rübe Christian, Melchior Patrick, Dzierma Yvonne
Department of Radiotherapy and Radiation Oncology, Saarland University Medical Centre, Homburg, Germany.
Siemens Healthcare GmbH, Technical Service, Erlangen, Germany.
Front Oncol. 2022 Jul 27;12:892923. doi: 10.3389/fonc.2022.892923. eCollection 2022.
Radiotherapy after breast-conserving therapy is a standard postoperative treatment of breast cancer, which can be carried out with a variety of irradiation techniques. The treatment planning must take into consideration detrimental effects on the neighbouring organs at risk-the lung, the heart, and the contralateral breast, which can include both short- and long-term effects represented by the normal tissue complication probability and secondary cancer risk.
In this planning study, we investigate intensity-modulated (IMRT) and three-dimensional conformal (3D-CRT) radiotherapy techniques including sequential or simultaneously integrated boosts as well as interstitial multicatheter brachytherapy boost techniques of 38 patients with breast-conserving surgery retrospectively. We furthermore develop a 3D-printed breast phantom add-on to allow for catheter placement and to measure the out-of-field dose using thermoluminescent dosimeters placed inside an anthropomorphic phantom. Finally, we estimate normal tissue complication probabilities using the Lyman-Kutcher-Burman model and secondary cancer risks using the linear non-threshold model (out-of-field) and the model by Schneider et al. (in-field).
The results depend on the combination of primary whole-breast irradiation and boost technique. The normal tissue complication probabilities for various endpoints are of the following order: 1%-2% (symptomatic pneumonitis, ipsilateral lung), 2%-3% (symptomatic pneumonitis, whole lung), and 1%-2% (radiation pneumonitis grade ≥ 2, whole lung). The additional relative risk of ischemic heart disease ranges from +25% to +35%. In-field secondary cancer risk of the ipsilateral lung in left-sided treatment is around 50 per 10,000 person-years for 20 years after exposure at age 55. Out-of-field estimation of secondary cancer risk results in approximately 5 per 10,000 person-years each for the contralateral lung and breast.
In general, 3D-CRT shows the best risk reduction in contrast to IMRT. Regarding the boost concepts, brachytherapy is the most effective method in order to minimise normal tissue complication probability and secondary cancer risk compared to teletherapy boost concepts. Hence, the 3D-CRT technique in combination with an interstitial multicatheter brachytherapy boost is most suitable in terms of risk avoidance for treating breast cancer with techniques including boost concepts.
保乳治疗后的放射治疗是乳腺癌的标准术后治疗方法,可采用多种照射技术。治疗计划必须考虑对邻近危险器官(肺、心脏和对侧乳房)的有害影响,这可能包括以正常组织并发症概率和继发癌症风险表示的短期和长期影响。
在这项计划研究中,我们回顾性研究了38例保乳手术患者的调强放疗(IMRT)和三维适形放疗(3D-CRT)技术,包括序贯或同步整合加量以及组织间多导管近距离放疗加量技术。我们还开发了一种3D打印的乳房模型附件,用于放置导管,并使用置于人体模型内的热释光剂量计测量野外剂量。最后,我们使用莱曼-库彻-伯曼模型估计正常组织并发症概率,并使用线性无阈模型(野外)和施奈德等人的模型(野内)估计继发癌症风险。
结果取决于原发全乳照射和加量技术的组合。各种终点的正常组织并发症概率如下:1%-2%(有症状肺炎;同侧肺),2%-3%(有症状肺炎;全肺),以及1%-2%(≥2级放射性肺炎;全肺)。缺血性心脏病的额外相对风险范围为+25%至+35%。55岁时接受照射后20年,左侧治疗中同侧肺的野内继发癌症风险约为每10000人年50例。对侧肺和乳房的野外继发癌症风险估计约为每10000人年各5例。
一般来说,与IMRT相比,3D-CRT显示出最佳的风险降低效果。关于加量概念,与远距离治疗加量概念相比,近距离放疗是将正常组织并发症概率和继发癌症风险降至最低的最有效方法。因此,就避免风险而言,3D-CRT技术与组织间多导管近距离放疗加量相结合最适合采用包括加量概念的技术治疗乳腺癌。